A BILL FOR AN ACT

CONCERNING THE PREVENTION OF SUBSTANCE USE DISORDERS.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov.)

Opioid and Other Substance Use Disorders Study Committee. The bill requires the commissioner of insurance (commissioner) to promulgate rules that establish diagnoses of covered conditions for which nonpharmacological alternatives to opioids are appropriate. Each health benefit plan is required to provide coverage for at least 6 physical therapy visits and 6 occupational therapy visits per year or 12 acupuncture visits per year, with a maximum of one copayment per year for 12 covered visits. The bill requires the commissioner to conduct an actuarial study to
determine the economic feasibility prior to including acupuncture as a covered alternative treatment. (section 1 of the bill).

The bill prohibits an insurance carrier (carrier) from limiting or excluding coverage for an atypical opioid or a nonopioid medication that is approved by the federal food and drug administration by mandating that a covered person undergo step therapy or obtain prior authorization if the atypical opioid or nonopioid medication is prescribed by the covered person's health care provider. The carrier is required to make the atypical opioid or nonopioid medication available at the lowest cost-sharing tier applicable to a covered opioid with the same indication (section 2).

The bill precludes a carrier that has a contract with a physical therapist, occupational therapist, or acupuncturist from prohibiting the physical therapist, occupational therapist, or acupuncturist from, or penalizing the physical therapist, occupational therapist, or acupuncturist for, providing a covered person information on the amount of the covered person's financial responsibility for the covered person's physical therapy, occupational therapy, or acupuncture services or from requiring the physical therapist, occupational therapist, or acupuncturist to charge or collect a copayment from a covered person that exceeds the total charges submitted by the physical therapist, occupational therapist, or acupuncturist. The commissioner is required to take action against a carrier that the commissioner determines is not complying with these prohibitions (section 3).

Current law limits an opioid prescriber from prescribing more than a 7-day supply of an opioid to a patient who has not had an opioid prescription within the previous 12 months unless certain conditions apply, and this prescribing limitation is set to repeal on September 1, 2021. The bill continues the prescribing limitation indefinitely (sections 4 through 10).

The bill requires the executive director of the department of regulatory agencies (department) to consult with the center for research into substance use disorder prevention, treatment, and recovery support strategies (center) and the state medical board to promulgate rules establishing competency-based continuing education requirements for physicians and physician assistants concerning prescribing practices for opioids (section 11).

The bill modifies requirements for adding prescription information to the prescription drug monitoring program (program) and allows the department of health care policy and financing and the health information organization network access to the program (sections 12 and 13).

The bill continues indefinitely the requirement that a health care provider query the program before prescribing a second fill for an opioid and requires each health care provider to query the program before prescribing a benzodiazepine, unless certain exceptions apply. The bill also requires the director of the division of professions and occupations
in the department to promulgate rules designating additional controlled substances and other prescription drugs to be tracked by the program. In addition to current law allowing medical examiners and coroners to query the program when conducting an autopsy, the bill allows medical examiners and coroners to query the program when conducting a death investigation (sections 13 through 15).

The bill appropriates money to:

* The department of public health and environment annually to address opioid and other substance use disorders through local public health agencies (section 16);
* The department of health care policy and financing to extend the operation of the substance use disorder screening, brief intervention, and referral to treatment grant program (section 17); and
* The department of human services for allocation to the center for continuing education activities for opioid prescribers, including education for prescribing benzodiazepines (section 18).

The bill directs the office of behavioral health in the department of human services to convene a collaborative with institutions of higher education, nonprofit agencies, and state agencies for the purpose of gathering feedback from local public health agencies, institutions of higher education, nonprofit agencies, and state agencies concerning evidence-based prevention practices (section 19).

Be it enacted by the General Assembly of the State of Colorado:

SECTION 1. In Colorado Revised Statutes, 10-16-104, add (23) as follows:

10-16-104. Mandatory coverage provisions - definitions - rules. (23) Nonpharmacological alternative treatment to opioids - rules. (a) Any health benefit plan, except supplemental policies covering a specified disease or other limited benefit, must provide coverage for nonpharmacological treatment as an alternative to opioids.

(b) The coverage required by this subsection (23) must:

(I) include, at the carriers' lowest cost-sharing tier, a
MINIMUM OF SIX PHYSICAL THERAPY VISITS, SIX OCCUPATIONAL THERAPY VISITS, SIX CHIROPRACTIC VISITS, AND SIX ACUPUNCTURE VISITS; AND

(II) NOT REQUIRE PRIOR AUTHORIZATION, AS DEFINED IN SECTION 10-16-112.5 (7)(d), FOR NONPHARMACOLOGICAL TREATMENTS AS AN ALTERNATIVE TO OPIOIDS.

(c) AT THE TIME OF A COVERED PERSON'S INITIAL VISIT FOR TREATMENT, A PHYSICAL THERAPIST, OCCUPATIONAL THERAPIST, ACUPUNCTURIST, OR CHIROPRACTOR SHALL NOTIFY THE COVERED PERSON'S CARRIER THAT THE COVERED PERSON HAS STARTED TREATMENT WITH THE PROVIDER.

SECTION 2. In Colorado Revised Statutes, amend 10-16-145.5 as follows:

10-16-145.5. Step therapy - prior authorization - prohibited - stage four advanced metastatic cancer - opioid prescription - definition - rules. (1) (a) Notwithstanding section 10-16-145, a carrier that provides coverage under a health benefit plan for the treatment of stage four advanced metastatic cancer shall not limit or exclude coverage under the health benefit plan for a drug THAT IS approved by the United States food and drug administration and that is on the carrier's prescription drug formulary by mandating that a covered person with stage four advanced metastatic cancer undergo step therapy if the use of the approved drug is consistent with:

(α) (I) The United States food and drug administration-approved indication or the national comprehensive cancer network drugs and biologics compendium indication for the treatment of stage four advanced metastatic cancer; or

(β) (II) Peer-reviewed medical literature.
(2) (b) For the purposes of this section SUBSECTION (1), "stage four advanced metastatic cancer" means cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other parts of the body.

(2) (a) Notwithstanding section 10-16-145, a carrier shall not limit or exclude coverage under a health benefit plan for a nonopioid or an atypical opioid that has the same indication as, and is prescribed by the covered person's provider as an alternative to, an opioid and that has been approved by the United States food and drug administration by:

(I) Mandating that a covered person undergo step therapy for the nonopioid or atypical opioid; or

(II) Requiring prior authorization for the nonopioid or atypical opioid.

(b) The carrier shall make the prescribed nonopioid or atypical opioid available to the covered person at the carrier's lowest cost-sharing tier under the health benefit plan applicable to a covered opioid that has the same indication.

(c) For the purposes of this section, "nonopioid or an atypical opioid" means analgesics with far lower fatality rates than pure opioid agonists as specified by rule of the commissioner.

SECTION 3. In Colorado Revised Statutes, add 10-16-152 as follows:

10-16-152. Disclosures - physical therapists - occupational therapists - acupuncturists - patients - carrier prohibitions - enforcement. (1) A carrier that has a contract with a physical
THERAPIST, AN OCCUPATIONAL THERAPIST, OR AN ACUPUNCTURIST SHALL NOT:

(a) **PROHIBIT** THE PHYSICAL THERAPIST, OCCUPATIONAL THERAPIST, OR ACUPUNCTURIST FROM PROVIDING A COVERED PERSON INFORMATION ON THE AMOUNT OF THE COVERED PERSON’S FINANCIAL RESPONSIBILITY FOR THE COVERED PERSON’S PHYSICAL THERAPY, OCCUPATIONAL THERAPY, OR ACUPUNCTURE SERVICES;

(b) **PENALIZE** THE PHYSICAL THERAPIST, OCCUPATIONAL THERAPIST, OR ACUPUNCTURIST FOR DISCLOSING THE INFORMATION DESCRIBED IN SUBSECTION (1)(a) OF THIS SECTION TO A COVERED PERSON OR PROVIDING A MORE AFFORDABLE ALTERNATIVE TO A COVERED PERSON;

(c) **REQUIRE** THE PHYSICAL THERAPIST, THE OCCUPATIONAL THERAPIST, OR THE ACUPUNCTURIST TO CHARGE OR COLLECT A COPAYMENT FROM A COVERED PERSON THAT EXCEEDS THE TOTAL CHARGES SUBMITTED BY THE PHYSICAL THERAPIST, OCCUPATIONAL THERAPIST, OR ACUPUNCTURIST.

(2) **IF** THE COMMISSIONER DETERMINES THAT A CARRIER HAS NOT COMPLIED WITH THIS SECTION, THE COMMISSIONER SHALL INSTITUTE A CORRECTIVE ACTION PLAN FOR THE CARRIER TO FOLLOW OR USE ANY OF THE COMMISSIONER’S ENFORCEMENT POWERS UNDER THIS TITLE 10 TO OBTAIN THE CARRIER’S COMPLIANCE WITH THIS SECTION.

**SECTION 4.** In Colorado Revised Statutes, 12-30-109, amend (1)(a) introductory portion, (1)(a)(I), (1)(a)(IV), (1)(b), and (4) introductory portion; amend as it exists until July 1, 2021, (2); repeal (5); and add (6) as follows:

(1) (a) An opioid prescriber shall not prescribe more than a seven-day supply of an opioid to a patient who has not had an opioid prescription in the last twelve months by that opioid prescriber and may exercise discretion to include a second fill for a seven-day supply. The limits on initial prescribing do not apply if, in the judgment of the opioid prescriber, the patient:

(I) Has chronic pain that typically lasts longer than ninety days or past the time of normal healing, as determined by the opioid prescriber, or following transfer of care from another opioid prescriber who practices the same profession and who prescribed an opioid to the patient;

(IV) Is undergoing palliative care or hospice care focused on providing the patient with relief from symptoms, pain, and stress resulting from a serious illness in order to improve quality of life; except that this subsection (1)(a)(IV) applies only if the opioid prescriber is a physician, a physician assistant, or an advanced practice nurse.

(b) Prior to prescribing the second fill of any opioid OR BENZODIAZEPINE prescription pursuant to this section, an opioid prescriber must comply with the requirements of section 12-280-404 (4). Failure to comply with section 12-280-404 (4) constitutes unprofessional conduct or grounds for discipline, as applicable, under section 12-220-130, 12-240-121, 12-255-120, 12-275-120, 12-290-108, or 12-315-112, as applicable to the particular opioid prescriber, only if the opioid prescriber repeatedly fails to comply.

(2) An opioid prescriber licensed pursuant to article 220, 240, 255, 275, 290, or 315 of this title 12 may prescribe opioids AND BENZODIAZEPINES electronically.
(4) As used in this section, "opioid prescriber" means:

This section is repealed, effective September 1, 2021.

(6) The executive director shall, by rule, limit the supply of a benzodiazepine that a prescriber may prescribe to a patient who has not had a benzodiazepine prescription in the last twelve months by that prescriber.

SECTION 5. In Colorado Revised Statutes, 12-30-109, amend as it exists from July 1, 2021, until July 1, 2023, (2) as follows:


An opioid prescriber licensed pursuant to article 220 or 315 of this title may prescribe opioids and benzodiazepines electronically.

SECTION 6. In Colorado Revised Statutes, 12-30-109, amend as it will become effective July 1, 2023, (2) as follows:


An opioid prescriber licensed pursuant to article 315 of this title may prescribe opioids and benzodiazepines electronically.

SECTION 7. In Colorado Revised Statutes, 12-220-111, amend (2) as follows:

12-220-111. Dentists may prescribe drugs - surgical operations - anesthesia - limits on prescriptions. (2) (a) A dentist is subject to the limitations on prescribing opioids specified in section 12-30-109.

(b) This subsection (2) is repealed, effective September 1, 2021.

SECTION 8. In Colorado Revised Statutes, amend 12-240-123 as follows:

12-240-123. Prescriptions - limitations. (4) A physician or
physician assistant is subject to the limitations on prescribing opioids specified in section 12-30-109.

(2) This section is repealed, effective September 1, 2021.

SECTION 9. In Colorado Revised Statutes, 12-255-112, amend (6) as follows:

12-255-112. Prescriptive authority - advanced practice nurses - limits on prescriptions - rules - financial benefit for prescribing prohibited. (6) (a) An advanced practice nurse with prescriptive authority pursuant to this section is subject to the limitations on prescribing opioids specified in section 12-30-109.

(b) This subsection (6) is repealed, effective September 1, 2021."

SECTION 10. In Colorado Revised Statutes, 12-275-113, amend (5) as follows:

12-275-113. Use of prescription and nonprescription drugs - limits on prescriptions. (5) (a) An optometrist is subject to the limitations on prescribing opioids specified in section 12-30-109.

(b) This subsection (5) is repealed, effective September 1, 2021.

SECTION 11. In Colorado Revised Statutes, 12-290-111, amend (3) as follows:

12-290-111. Prescriptions - requirement to advise patients - limits on prescriptions. (3) (a) A podiatrist is subject to the limitations on prescribing opioids specified in section 12-30-109.

(b) This subsection (3) is repealed, effective September 1, 2021.

SECTION 12. In Colorado Revised Statutes, amend 12-315-126 as follows:

12-315-126. Prescriptions - limitations. (†) A veterinarian is
subject to the limitations on prescribing opioids to the limitations on prescribing opioids specified in section 12-30-109.

(2) This section is repealed, effective September 1, 2021.

SECTION 13. In Colorado Revised Statutes, 12-240-130, repeal (3) as follows:

12-240-130. Procedure - registration - fees. (3) Applicants for relicensure shall not be required to attend and complete continuing medical education programs, except as directed by the board to correct deficiencies of training or education as directed under section 12-240-125 (5)(e)(III)(B).

SECTION 14. In Colorado Revised Statutes, add 12-240-146 as follows:

12-240-146. Continuing education - competency standards for prescribing opioids - rules. The board, in consultation with the Center for Research into Substance Use Disorder Prevention, Treatment, and Recovery Support Strategies established in section 27-80-118, shall promulgate rules to establish competency-based standards for continuing medical education for physicians and physician assistants concerning the prescribing practices for opioids. The board shall require fulfillment of the continuing education requirements as a requirement for relicensure or renewal.

SECTION 15. In Colorado Revised Statutes, 12-280-403, amend (1) introductory portion, (1)(c), (1)(e), (1)(f), (3), and (4); and add (1)(g) and (2)(e) as follows:

12-280-403. Prescription drug use monitoring program - registration required. (1) The board shall develop or procure a
prescription controlled substance electronic program to track information regarding prescriptions for controlled substances AND OTHER DRUGS AS REQUIRED BY RULES PROMULGATED BY THE BOARD dispensed in Colorado, including the following information:

(c) The name and amount of the controlled substance OR OTHER PRESCRIPTION DRUG AS REQUIRED BY RULES OF THE BOARD;

(e) The name of the dispensing pharmacy; and

(f) Any other data elements necessary to determine whether a patient is visiting multiple practitioners or pharmacies, or both, to receive the same or similar medication; AND

(g) BEGINNING JANUARY 1, 2021, THE NAME OF THE PERSON PAYING FOR THE PRESCRIPTION.

(2) (e) OTHER THAN AN ANNUAL FEE AUTHORIZED PURSUANT TO SECTION 12-280-405 (3), THE BOARD SHALL NOT CHARGE A FEE OR OTHER ASSESSMENT AGAINST A PRACTITIONER, PHARMACIST, OR DESIGNEE OF EITHER A PRACTITIONER OR PHARMACIST FOR REGISTERING OR MAINTAINING AN ACCOUNT WITH THE PROGRAM.

(3) Each practitioner and each dispensing pharmacy shall disclose to a patient receiving a controlled substance OR OTHER PRESCRIPTION DRUG AS REQUIRED BY RULES PROMULGATED BY THE BOARD that his or her THE PATIENT'S identifying prescription information will be entered into the program database and may be accessed for limited purposes by specified individuals.

(4) The board shall establish a method and format for PHARMACISTS, PHARMACISTS' DESIGNEES, AND prescription drug outlets to convey the necessary information to the board or its designee. The method must not require more than a one-time entry of data per patient
per prescription by a prescription drug outlet. BY JANUARY 1, 2021, THE
METHOD ESTABLISHED BY THE BOARD PURSUANT TO THIS SUBSECTION (4)
SHALL REQUIRE EACH PHARMACIST, PHARMACIST’S DESIGNEE, OR
PRESCRIPTION DRUG OUTLET TO ENTER EACH PRESCRIPTION DISPENSED IN
THIS STATE OR TO AN ADDRESS IN THIS STATE, INCLUDING PRESCRIPTIONS
NOT PAID FOR BY A THIRD-PARTY PAYER, INTO THE PROGRAM DATABASE
DAILY AFTER EACH PRESCRIPTION IS DISPENSED.

SECTION 16. In Colorado Revised Statutes, 12-280-404, amend
(3)(b), (3)(c)(I), (3)(h), (3)(l)(I), (4)(c), (5), and (7); repeal (4)(e); and
add (3)(m), (4)(a.5), and (4)(f) as follows:

(3) The program is available for query only to the following persons or
group of persons:

(b) Any practitioner with the statutory authority to prescribe
controlled substances OR OTHER DRUGS THAT MAY BE SUBJECT TO A
PROGRAM QUERY, or an individual designated by the practitioner to act on
his or her THE PRACTITIONER’S behalf in accordance with section
12-280-403 (2)(b), to the extent the query relates to a current patient of
the practitioner. The practitioner or his or her THE PRACTITIONER’S
designee shall identify his or her area of health care specialty or practice
upon the initial query of the program.

(c) (I) Any veterinarian with statutory authority to prescribe
controlled substances OR OTHER DRUGS THAT MAY BE SUBJECT TO A
PROGRAM QUERY, to the extent the query relates to a current patient or to
a client and if the veterinarian, in the exercise of professional judgment,
has a reasonable basis to suspect the client has committed drug abuse or
has mistreated an animal.
The individual who is the recipient of a controlled substance prescription for a controlled substance or other drug that may be subject to a program query so long as the information released is specific to the individual;

(l) A medical examiner who is a physician licensed pursuant to article 240 of this title, whose license is in good standing, and who is located and employed in the state of Colorado, or a coroner elected pursuant to section 30-10-601, if:

(i) The information released is specific to an individual who is the subject of an autopsy or a death investigation conducted by the medical examiner or coroner;

(m) The department of health care policy and financing, for the purposes of care coordination and utilization review pertaining to recipients of medical assistance under articles 4, 5, and 6 of title 25.5, as long as the department's use of the program data is consistent with the federal "Health Insurance Portability and Accountability Act of 1996", Pub.L. 104-191, as amended, and any implementing regulations, including the requirement to remove any personally identifying information unless exempted from the requirement.

(4) (a.5) Each practitioner or the practitioner's designee shall query the program before prescribing a second fill for a benzodiazepine to a patient unless the benzodiazepine is prescribed to treat a patient in hospice or to treat a seizure or seizure disorder, alcohol withdrawal, or a neurological emergency event including a post-traumatic brain injury.

(c) A practitioner or his or her the practitioner's designee
complies with this subsection (4) if the practitioner or the practitioner's designee attempts to access the program prior to prescribing the second fill for an opioid or a benzodiazepine and the program is not available or is inaccessible due to technical failure.

(c) This subsection (4) is repealed, effective September 1, 2021.

(f) The board shall promulgate rules designating additional controlled substances and other prescription drugs to be tracked through the program pursuant to section 12-280-403 (1) that have potential for abuse or have potential for an adverse drug interaction with a controlled substance.

(5) Other than the fee authorized by section 12-280-405 (3), the board shall not charge a practitioner, or pharmacy, pharmacist, or designee of a practitioner or pharmacist who transmits data in compliance with the operation and maintenance of the program a fee for the transmission of the data and shall not charge a practitioner, pharmacist, or designee of a practitioner or pharmacist a fee to access the database.

(7) (a) The board shall provide a means of sharing information about individuals whose information is recorded in the program with out-of-state health care practitioners and law enforcement officials that meet the requirements of subsection (3)(b), (3)(d), or (3)(g) of this section.

(b) By January 1, 2021, the board shall provide a means of sharing prescription information with the health information organization network, as defined in section 25-3.5-103 (8.5), in order to work collaboratively with the statewide health information exchanges designated by the department of health.
CARE POLICY AND FINANCING. USE OF THE INFORMATION MADE AVAILABLE PURSUANT TO THIS SUBSECTION (7)(b) IS SUBJECT TO PRIVACY AND SECURITY PROTECTIONS IN STATE LAW AND THE FEDERAL "HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996", PUB.L.104-191, AS AMENDED, AND ANY IMPLEMENTING REGULATIONS.

SECTION 17. In Colorado Revised Statutes, 12-280-407, amend (2) as follows:

12-280-407. Prescription drug outlets - prescribers - responsibilities - liability. (2) A practitioner who has, in good faith, written a prescription for a controlled substance OR OTHER DRUG THAT MAY BE SUBJECT TO A PROGRAM QUERY to a patient is not liable for information submitted to the program. A practitioner WHO or prescription drug outlet who THAT has, in good faith, submitted the required information to the program is not liable for participation in the program.

SECTION 18. In Colorado Revised Statutes, 12-280-408, amend (2) as follows:

12-280-408. Exemption - waiver. (2) A prescription drug outlet that does not report controlled substance data OR DATA ON OTHER PRESCRIPTION DRUGS THAT MAY BE SUBJECT TO A PROGRAM QUERY to the program due to a lack of electronic automation of the outlet's business may apply to the board for a waiver from the reporting requirements.

SECTION 19. In Colorado Revised Statutes, amend 25-1-521 as follows:

25-1-521. State department - local public health agencies - address substance use disorders - appropriation. (†) For the 2019-20 STATE fiscal year AND EACH STATE FISCAL YEAR THEREAFTER, the general assembly shall appropriate two million dollars to the state department to
address opioid and substance use disorders through public health interventions and to work with community partners, including county and district public health agencies, to address opioid and other substance use priorities throughout the state. The state department may use the money for data collection, analysis, and dissemination activities related to opioid and other substance use disorders at the state and local levels, including community health assessments and improvement planning. The state department shall consider the goal of addressing the needs of underserved populations and communities when addressing opioid and substance use disorders. The state department may use up to five hundred thousand dollars of the money annually appropriated pursuant to this subsection (1) for administrative costs and other activities related to the purposes of this section.

(2) This section is repealed, effective July 1, 2020.

SECTION 20. In Colorado Revised Statutes, 25.5-5-208, amend (1) introductory portion; and add (3) as follows:

25.5-5-208. Additional services - training - grants - screening, brief intervention, and referral. (1) On or after July 1, 2018, the state department shall grant, through a competitive grant program, one million five hundred thousand dollars to one or more organizations to operate a substance abuse disorder screening, brief intervention, and referral to treatment practice grant program. In reviewing grant applications and selecting participants for the grant program, the state department shall consider the goal of addressing the needs of underserved populations and communities. The grant program must require:

(3) For the 2020-21 state fiscal year through the 2023-24
STATE FISCAL YEAR, THE GENERAL ASSEMBLY SHALL APPROPRIATE FIVE
HUNDRED THOUSAND DOLLARS FROM THE MARIJUANA TAX CASH FUND
CREATED IN SECTION 39-28.8-501 (1) TO THE STATE DEPARTMENT FOR THE
SUBSTANCE USE DISORDER SCREENING, BRIEF INTERVENTION, AND
REFERRAL TO TREATMENT GRANT PROGRAM DESCRIBED IN SUBSECTION (1)
OF THIS SECTION. THE STATE DEPARTMENT SHALL USE THE MONEY FOR
EXPANDED TRAINING AND TECHNICAL ASSISTANCE IN ORDER TO MONITOR
FIDELITY TO THE SCREENING, BRIEF INTERVENTION, AND REFERRAL TO
TREATMENT MODEL THROUGH QUALITATIVE AND QUANTITATIVE DATA
COLLECTION AND ANALYSIS.

(4)(a) as follows:

27-80-118. Center for research into substance use disorder
prevention, treatment, and recovery support strategies - legislative
declaration - established - repeal. (4) (a) (I) The center shall develop
and implement a series of continuing education activities designed to help
a prescriber of pain medication to safely and effectively manage patients
with pain and, when appropriate, prescribe opioids or medication-assisted
treatment. THE EDUCATIONAL ACTIVITIES MUST ALSO INCLUDE BEST
PRACTICES FOR PRESCRIBING BENZODIAZEPINES AND THE POTENTIAL HARM
OF INAPPROPRIATELY LIMITING PRESCRIPTIONS TO CHRONIC PAIN
PATIENTS. The educational activities must apply to physicians, physician
assistants, nurses, and dentists, WITH AN EMPHASIS ON PHYSICIANS,
PHYSICIAN ASSISTANTS, NURSES, AND DENTISTS SERVING UNDERSERVED
POPULATIONS AND COMMUNITIES.

(II) FOR THE STATE FISCAL YEARS 2020-21 THROUGH 2024-25, THE
GENERAL ASSEMBLY SHALL APPROPRIATE TWO HUNDRED FIFTY THOUSAND
DOLLARS PER YEAR FROM THE MARIJUANA TAX CASH FUND CREATED IN
SECTION 39-28.8-501 (1) TO THE DEPARTMENT FOR ALLOCATION TO THE
CENTER FOR THE PURPOSES OF THIS SUBSECTION (4).

SECTION 22. In Colorado Revised Statutes, add 27-80-124 as
follows:

27-80-124. Colorado substance use disorders prevention
collaborative - created - mission - administration - repeal. (1) The
office of behavioral health shall convene and administer a
colorado substance use disorders prevention collaborative
with institutions of higher education, nonprofit agencies, and
state agencies, referred to in this section as the
"collaborative", for the purpose of gathering feedback from
local public health agencies, institutions of higher education,
nonprofit agencies, and state agencies concerning
evidence-based prevention practices to fulfill the mission stated
in subsection (2) of this section.

(2) The mission of the collaborative is to:

(a) Coordinate with and assist state agencies and
communities to strengthen Colorado's prevention
infrastructure and to implement a statewide strategic plan for
primary prevention of substance use disorders for state fiscal
years 2020-21 through 2023-24;

(b) Advance the use of tested and effective prevention
programs and practices through education, outreach, advocacy,
and technical assistance, with an emphasis on addressing the
needs of underserved populations and communities;

(c) Direct efforts to raise public awareness of the cost
(d) PROVIDE DIRECT TRAINING AND TECHNICAL ASSISTANCE TO
COMMUNITIES REGARDING SELECTION, IMPLEMENTATION, AND
SUSTAINMENT OF TESTED AND EFFECTIVE PRIMARY PREVENTION
PROGRAMS;

(e) PURSUE LOCAL AND STATE POLICY CHANGES THAT ENHANCE
THE USE OF TESTED AND EFFECTIVE PRIMARY PREVENTION PROGRAMS;

(f) ADVISE STATE AGENCIES AND COMMUNITIES REGARDING NEW
AND INNOVATIVE PRIMARY PREVENTION PROGRAMS AND PRACTICES;

(g) SUPPORT FUNDING EFFORTS IN ORDER TO ALIGN FUNDING AND
SERVICES AND COMMUNICATE WITH COMMUNITIES ABOUT FUNDING
STRATEGIES;

(h) WORK WITH KEY STATE AND COMMUNITY STAKEHOLDERS TO
ESTABLISH A MINIMUM STANDARD FOR PRIMARY PREVENTION PROGRAMS
IN COLORADO; AND

(i) WORK WITH PREVENTION SPECIALISTS AND EXISTING TRAINING
 AGENCIES TO PROVIDE AND SUPPORT TRAINING TO STRENGTHEN
COLORADO'S PREVENTION WORKFORCE.

(3) THE OFFICE OF BEHAVIORAL HEALTH AND THE COLLABORATIVE
SHALL:

(a) ESTABLISH COMMUNITY-BASED PREVENTION COALITIONS AND
 DELIVERY SYSTEMS TO REDUCE SUBSTANCE MISUSE;

(b) IMPLEMENT EFFECTIVE PRIMARY PREVENTION PROGRAMS IN
 COLORADO COMMUNITIES WITH THE GOAL OF INCREASING THE NUMBER OF
PROGRAMS TO REACH THOSE IN NEED STATEWIDE; AND

(c) COORDINATE WITH DESIGNATED STATE AGENCIES AND OTHER
ORGANIZATIONS TO PROVIDE PREVENTION SCIENCE TRAINING TO
SYSTEMIZE, UPDATE, EXPAND, AND STRENGTHEN PREVENTION CERTIFICATION TRAINING AND PROVIDE CONTINUING EDUCATION TO PREVENTION SPECIALISTS.

(4) IN ORDER TO IMPLEMENT AND PROVIDE SUSTAINABILITY TO THE COLLABORATIVE, FOR STATE FISCAL YEARS 2020-21 THROUGH 2023-24, THE GENERAL ASSEMBLY SHALL APPROPRIATE MONEY FROM THE MARIJUANA TAX CASH FUND CREATED IN SECTION 39-28.8-501 (1) TO THE OFFICE OF BEHAVIORAL HEALTH TO ACCOMPLISH THE MISSION OF THE COLLABORATIVE.

(5) THE OFFICE OF BEHAVIORAL HEALTH SHALL REPORT ITS PROGRESS TO THE GENERAL ASSEMBLY ON OR BEFORE SEPTEMBER 1, 2021, AND EACH SEPTEMBER 1 THROUGH SEPTEMBER 1, 2024.

(6) THIS SECTION IS REPEALED, EFFECTIVE SEPTEMBER 30, 2024.

SECTION 23. Safety clause. The general assembly hereby finds, determines, and declares that this act is necessary for the immediate preservation of the public peace, health, or safety.